Wayne Koberstein

  1. Art Of The Startup — Making New Waves 3/1/2022

    As Shoreline’s chairman, CEO, and cofounder, Dr. Kleanthis Xanthopoulos draws on his experience of several decades, starting and running companies that aim to overturn prevailing practices in areas of medicine where practice makes imperfect, with treatments that disappoint patients or prove expensive and impractical for many.

  2. Companies To Watch: MiroBio 2/1/2022

    MiroBio is precisely targeting checkpoint receptors with agonist antibodies for better treatments in autoimmunity.

  3. Companies To Watch: Qlaris Bio 1/4/2022

    Qlaris Bio is striking at an unaddressed target in the intraocular pressure of glaucoma.

  4. Tackling Uncertainty In Drug R&D 1/4/2022

    Can bioinformatics help biopharma companies manage their expectations and limit their risk in drug R&D? Ben Zeskind, a CEO who has built and bet his entire career on a positive answer to that question, discusses his reasons for optimism.

  5. Can the FDA & CDC Recover from Recent Politics? 12/1/2021

    Five leading biopharma executives discuss the perils of political influence over the FDA and CDC and why every member of the industry should care.

  6. Long Hauler In The Antibiotics Space 11/1/2021

    For Ted Schroeder, CEO of Nabriva Therapeutics, the road of his biopharma career led him into the antibiotics space, a mighty steep climb in the biopharma industry.

  7. Companies To Watch: Graphite Bio 11/1/2021

    Graphite Bio focuses on precise repair of genes that cause sickness, starting with Sickle Cell Disease.

  8. Companies To Watch: Atea Pharmaceuticals 10/1/2021

    Atea Pharmaceuticals is creating new nucleotide antivirals, including one the company is jointly developing with Roche to fight COVID-19.

  9. Going Precommercial — From The Commercial World 10/1/2021

    Nancy Lurker, a veteran Big-Pharma marketer, now runs a small biopharma. And she admits, “the business models are very, very different.”

  10. Companies To Watch: AltruBio 9/1/2021

    AltruBio’s new approach — regulating a checkpoint to mediate T cells in immune diseases — can surprise people more familiar with checkpoint-blocking cancer treatments now on the market.